← Back to Clinical Trials
Recruiting NCT07401732

NCT07401732 Dysphagia in Rheumatoid Arthritis

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07401732
Status Recruiting
Phase
Sponsor Tanta University
Condition Rheumatoid Arthritis (RA
Study Type OBSERVATIONAL
Enrollment 137 participants
Start Date 2026-02-07
Primary Completion 2026-05

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
flexible fiberoptic pharyngolaryngoscopy

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 137 participants in total. It began in 2026-02-07 with a primary completion date of 2026-05.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The primary goal of this cross-sectional study is to assess risk factors/predictors for dysphagia severity in RA. The secondary goals include demonstrating whether flexible fiberoptic pharyngolaryngoscopy can diagnose joint-affection-induced dysphagia in patients with rheumatoid arthritis (RA) and whether both oropharyngeal and esophageal dysphagia are present among these patients. The main questions it aims to answer are * What are the predictors that are associated with dysphagia severity via flexible fiberoptic pharyngolaryngoscopy in rheumatoid arthritis patients? * Whether flexible fiberoptic pharyngolaryngoscopy can diagnose joint-affection-induced dysphagia in patients with RA? * Whether both oropharyngeal and esophageal dysphagia are present in patients with RA?

Eligibility Criteria

Inclusion Criteria: * Patients with Rheumatoid arthritis defined by the American College of Rheumatology/European League Against Rheumatism collaborative initiative (ACR/EULAR) 2010 classification criteria. * Patients aged above 18 years old, well-orientated, and cooperative. Exclusion Criteria: * concomitant cancer diagnosis, pregnancy. * jaw-related traumas, teeth and gum diseases. * other rheumatologic conditions * other comorbidities. * other causes of TMJ arthritis, patients with TMJ, palatal or tongue congenital abnormalities, and patients who underwent TMJ injections in the last six months. * Patients with any language disorders or intellectually handicapped (as certain questions depend on the patient's ability to comprehend and express their emotions regarding their issue) and patients with anatomical anomalies impeding the functionality of flexible nasofibroscopy. * Any apparent causes of dysphagia other than RA.

Contact & Investigator

Central Contact

Aliaa MA Farag, MD

✉ aliaa.mamdouh@med.tanta.edu.eg

📞 +201069468486

Principal Investigator

Aliaa MA Farag, MD

PRINCIPAL INVESTIGATOR

Tanta University Faculty of Medicine

Frequently Asked Questions

Who can join the NCT07401732 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Rheumatoid Arthritis (RA. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07401732 currently recruiting?

Yes, NCT07401732 is actively recruiting participants. Contact the research team at aliaa.mamdouh@med.tanta.edu.eg for enrollment information.

Where is the NCT07401732 trial being conducted?

This trial is being conducted at Tanta, Egypt, Tanta, Egypt.

Who is sponsoring the NCT07401732 clinical trial?

NCT07401732 is sponsored by Tanta University. The principal investigator is Aliaa MA Farag, MD at Tanta University Faculty of Medicine. The trial plans to enroll 137 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology